Alan Breier - Publications

Affiliations: 
Lilly, Lilly, PA, United States 

204 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Rao KN, Sentir AM, Engleman EA, Bell RL, Hulvershorn LA, Breier A, Chambers RA. Toward early estimation and treatment of addiction vulnerability: radial arm maze and N-acetyl cysteine before cocaine sensitization or nicotine self-administration in neonatal ventral hippocampal lesion rats. Psychopharmacology. PMID 27640177 DOI: 10.1007/s00213-016-4421-8  1
2015 Vohs JL, Hummer TA, Yung MG, Francis MM, Lysaker PH, Breier A. Metacognition in Early Phase Psychosis: Toward Understanding Neural Substrates. International Journal of Molecular Sciences. 16: 14640-54. PMID 26132568 DOI: 10.3390/ijms160714640  1
2015 Vohs JL, Lysaker PH, Liffick E, Francis MM, Leonhardt BL, James A, Buck KD, Hamm JA, Minor KS, Mehdiyoun N, Breier A. Metacognitive capacity as a predictor of insight in first-episode psychosis. The Journal of Nervous and Mental Disease. 203: 372-8. PMID 25900550 DOI: 10.1097/NMD.0000000000000291  1
2015 Francis MM, Hummer TA, Vohs JL, Yung MG, Liffick E, Mehdiyoun NF, Radnovich AJ, McDonald BC, Saykin AJ, Breier A. Functional neuroanatomical correlates of episodic memory impairment in early phase psychosis. Brain Imaging and Behavior. PMID 25749917 DOI: 10.1007/s11682-015-9357-9  1
2015 Jarskog LF, Lowy MT, Grove RA, Keefe RS, Horrigan JP, Ball MP, Breier A, Buchanan RW, Carter CS, Csernansky JG, Goff DC, Green MF, Kantrowitz JT, Keshavan MS, Laurelle M, et al. A Phase II study of a histamine H₃ receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy. Schizophrenia Research. 164: 136-42. PMID 25728831 DOI: 10.1016/j.schres.2015.01.041  1
2014 Vohs JL, Lysaker PH, Francis MM, Hamm J, Buck KD, Olesek K, Outcalt J, Dimaggio G, Leonhardt B, Liffick E, Mehdiyoun N, Breier A. Metacognition, social cognition, and symptoms in patients with first episode and prolonged psychoses. Schizophrenia Research. 153: 54-9. PMID 24503175 DOI: 10.1016/j.schres.2014.01.012  1
2013 Kim DJ, Bolbecker AR, Howell J, Rass O, Sporns O, Hetrick WP, Breier A, O'Donnell BF. Disturbed resting state EEG synchronization in bipolar disorder: A graph-theoretic analysis. Neuroimage. Clinical. 2: 414-23. PMID 24179795 DOI: 10.1016/j.nicl.2013.03.007  1
2012 Rass O, Forsyth JK, Bolbecker AR, Hetrick WP, Breier A, Lysaker PH, O'Donnell BF. Computer-assisted cognitive remediation for schizophrenia: a randomized single-blind pilot study. Schizophrenia Research. 139: 92-8. PMID 22682988 DOI: 10.1016/j.schres.2012.05.016  1
2012 Ayalew M, Le-Niculescu H, Levey DF, Jain N, Changala B, Patel SD, Winiger E, Breier A, Shekhar A, Amdur R, Koller D, Nurnberger JI, Corvin A, Geyer M, Tsuang MT, et al. Convergent functional genomics of schizophrenia: from comprehensive understanding to genetic risk prediction. Molecular Psychiatry. 17: 887-905. PMID 22584867 DOI: 10.1038/mp.2012.37  1
2012 Rass O, Forsyth JK, Krishnan GP, Hetrick WP, Klaunig MJ, Breier A, O'Donnell BF, Brenner CA. Auditory steady state response in the schizophrenia, first-degree relatives, and schizotypal personality disorder. Schizophrenia Research. 136: 143-9. PMID 22285558 DOI: 10.1016/j.schres.2012.01.003  1
2011 Breier A. Anxiety disorders and antipsychotic drugs: a pressing need for more research. The American Journal of Psychiatry. 168: 1012-4. PMID 21969042 DOI: 10.1176/appi.ajp.2011.11071049  1
2011 Ahn WY, Rass O, Fridberg DJ, Bishara AJ, Forsyth JK, Breier A, Busemeyer JR, Hetrick WP, Bolbecker AR, O'Donnell BF. Temporal discounting of rewards in patients with bipolar disorder and schizophrenia. Journal of Abnormal Psychology. 120: 911-21. PMID 21875166 DOI: 10.1037/a0023333  1
2010 Perlis RH, Adams DH, Fijal B, Sutton VK, Farmen M, Breier A, Houston JP. Genetic association study of treatment response with olanzapine/fluoxetine combination or lamotrigine in bipolar I depression. The Journal of Clinical Psychiatry. 71: 599-605. PMID 20021991 DOI: 10.4088/JCP.08m04632gre  1
2010 Liffick E, Breier A. Pharmacotherapy of first-episode schizophrenia Psychopharm Review. 45: 41-48.  1
2009 Kane JM, Osuntokun O, Kryzhanovskaya LA, Xu W, Stauffer VL, Watson SB, Breier A. A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. The Journal of Clinical Psychiatry. 70: 572-81. PMID 19323965 DOI: 10.4088/JCP.08m04421  1
2009 Spann M, Lindborg S, Seaman J, Baker R, Dunayevich E, Breier A. Bayesian adaptive non-inferiority with safety assessment: retrospective case study to highlight potential benefits and limitations of the approach. Journal of Psychiatric Research. 43: 561-7. PMID 18804218 DOI: 10.1016/j.jpsychires.2008.07.009  1
2009 Breier A, Shekhar A. Innovative therapeutics for schizophrenia Psychopharm Review. 44: 17-24.  1
2008 Hawkins KA, Keefe RS, Christensen BK, Addington J, Woods SW, Callahan J, Zipursky RB, Perkins DO, Tohen M, Breier A, McGlashan TH. Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America Double Blind Treatment Study. Schizophrenia Research. 105: 1-9. PMID 18774696 DOI: 10.1016/j.schres.2008.07.008  1
2008 Adams DH, Close S, Farmen M, Downing AM, Breier A, Houston JP. Dopamine receptor D3 genotype association with greater acute positive symptom remission with olanzapine therapy in predominately caucasian patients with chronic schizophrenia or schizoaffective disorder. Human Psychopharmacology. 23: 267-74. PMID 18320559 DOI: 10.1002/hup.930  1
2008 Patel JK, Pinals DA, Breier A, First MB. Schizophrenia and Other Psychoses Psychiatry: Third Edition. 1: 1201-1282. DOI: 10.1002/9780470515167.ch65  1
2007 Hoffman RE, Woods SW, Hawkins KA, Pittman B, Tohen M, Preda A, Breier A, Glist J, Addington J, Perkins DO, McGlashan TH. Extracting spurious messages from noise and risk of schizophrenia-spectrum disorders in a prodromal population. The British Journal of Psychiatry : the Journal of Mental Science. 191: 355-6. PMID 17906248 DOI: 10.1192/bjp.bp.106.031195  1
2007 Houston JP, Adams DH, Kirkwood SC, Farmen M, Downing AM, Breier A. Neuroreceptor gene polymorphisms and olanzapine depressive symptom response in schizophrenia. Journal of Clinical Psychopharmacology. 27: 520-3. PMID 17873692 DOI: 10.1097/JCP.0b013e31814f4d82  1
2007 Breier A, Alphs L, Binneman B. Wayne Fenton's impact on industry. Schizophrenia Bulletin. 33: 1154-5. PMID 17562696 DOI: 10.1093/schbul/sbm068  1
2007 Perry EB, Cramer JA, Cho HS, Petrakis IL, Karper LP, Genovese A, O'Donnell E, Krystal JH, D'Souza DC. Psychiatric safety of ketamine in psychopharmacology research. Psychopharmacology. 192: 253-60. PMID 17458544 DOI: 10.1007/s00213-007-0706-2  1
2006 Breier A, Bohácová V, Docolomanský P. Inhibition of (Na(+)/K(+))-ATPase by Cibacron Blue 3G-A and its analogues. General Physiology and Biophysics. 25: 439-53. PMID 17356235  0.01
2006 McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW, Hawkins KA, Hoffman RE, Preda A, Epstein I, Addington D, Lindborg S, Trzaskoma Q, Tohen M, Breier A. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. The American Journal of Psychiatry. 163: 790-9. PMID 16648318 DOI: 10.1176/appi.ajp.163.5.790  1
2006 Carlson C, Hornbuckle K, DeLisle F, Kryzhanovskaya L, Breier A, Cavazzoni P. Diabetes mellitus and antipsychotic treatment in the United Kingdom. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 16: 366-75. PMID 16356695 DOI: 10.1016/j.euroneuro.2005.11.002  1
2006 Keefe RS, Young CA, Rock SL, Purdon SE, Gold JM, Breier A. One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. Schizophrenia Research. 81: 1-15. PMID 16202565 DOI: 10.1016/j.schres.2005.07.038  1
2005 Chou KL, Messing S, Oakes D, Feldman PD, Breier A, Friedman JH. Drug-induced psychosis in Parkinson disease: phenomenology and correlations among psychosis rating instruments. Clinical Neuropharmacology. 28: 215-9. PMID 16239760 DOI: 10.1097/01.wnf.0000180228.77802.32  1
2005 Breier A, Berg PH, Thakore JH, Naber D, Gattaz WF, Cavazzoni P, Walker DJ, Roychowdhury SM, Kane JM. Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. The American Journal of Psychiatry. 162: 1879-87. PMID 16199834 DOI: 10.1176/appi.ajp.162.10.1879  1
2005 Breier A. Developing drugs for cognitive impairment in schizophrenia. Schizophrenia Bulletin. 31: 816-22. PMID 16150959 DOI: 10.1093/schbul/sbi051  1
2005 Deberdt WG, Dysken MW, Rappaport SA, Feldman PD, Young CA, Hay DP, Lehman DL, Dossenbach M, Degenhardt EK, Breier A. Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 13: 722-30. PMID 16085789 DOI: 10.1176/appi.ajgp.13.8.722  1
2005 Silva de Lima M, de Jesus Mari J, Breier A, Maria Costa A, Pondé de Sena E, Hotopf M. Quality of life in schizophrenia: a multicenter, randomized, naturalistic, controlled trial comparing olanzapine to first-generation antipsychotics. The Journal of Clinical Psychiatry. 66: 831-8. PMID 16013897  1
2005 Haro JM, Edgell ET, Novick D, Alonso J, Kennedy L, Jones PB, Ratcliffe M, Breier A. Effectiveness of antipsychotic treatment for schizophrenia: 6-month results of the Pan-European Schizophrenia Outpatient Health Outcomes (SOHO) study. Acta Psychiatrica Scandinavica. 111: 220-31. PMID 15701107 DOI: 10.1111/j.1600-0447.2004.00450.x  1
2005 Deberdt W, Winokur A, Cavazzoni PA, Trzaskoma QN, Carlson CD, Bymaster FP, Wiener K, Floris M, Breier A. Amantadine for weight gain associated with olanzapine treatment. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 15: 13-21. PMID 15572269 DOI: 10.1016/j.euroneuro.2004.03.005  1
2005 Krystal JH, Abi-Saab W, Perry E, D'Souza DC, Liu N, Gueorguieva R, McDougall L, Hunsberger T, Belger A, Levine L, Breier A. Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology. 179: 303-9. PMID 15309376 DOI: 10.1007/s00213-004-1982-8  1
2004 Namjoshi MA, Risser R, Shi L, Tohen M, Breier A. Quality of life assessment in patients with bipolar disorder treated with olanzapine added to lithium or valproic acid. Journal of Affective Disorders. 81: 223-9. PMID 15337326 DOI: 10.1016/j.jad.2003.07.005  1
2004 Mitropoulou V, Goodman M, Sevy S, Elman I, New AS, Iskander EG, Silverman JM, Breier A, Siever LJ. Effects of acute metabolic stress on the dopaminergic and pituitary-adrenal axis activity in patients with schizotypal personality disorder. Schizophrenia Research. 70: 27-31. PMID 15246460 DOI: 10.1016/j.schres.2003.10.008  1
2004 Elman I, Rott D, Green AI, Langleben DD, Lukas SE, Goldstein DS, Breier A. Effects of pharmacological doses of 2-deoxyglucose on plasma catecholamines and glucose levels in patients with schizophrenia. Psychopharmacology. 176: 369-75. PMID 15179540 DOI: 10.1007/s00213-004-1890-y  1
2004 Cavazzoni P, Mukhopadhyay N, Carlson C, Breier A, Buse J. Retrospective analysis of risk factors in patients with treatment-emergent diabetes during clinical trials of antipsychotic medications. The British Journal of Psychiatry. Supplement. 47: S94-101. PMID 15056601 DOI: 10.1192/bjp.184.47.s94  1
2004 Hawkins KA, Addington J, Keefe RS, Christensen B, Perkins DO, Zipurksy R, Woods SW, Miller TJ, Marquez E, Breier A, McGlashan TH. Neuropsychological status of subjects at high risk for a first episode of psychosis. Schizophrenia Research. 67: 115-22. PMID 14984870 DOI: 10.1016/j.schres.2003.08.007  1
2004 Zhao Z, Namjoshi M, Barber BL, Loosbrock DL, Tunis SL, Zhu B, Breier A. Economic outcomes associated with switching individuals with schizophrenia between risperidone and olanzapine: findings from a large US claims database. Cns Drugs. 18: 157-64. PMID 14871159 DOI: 10.2165/00023210-200418030-00002  1
2004 De Deyn PP, Carrasco MM, Deberdt W, Jeandel C, Hay DP, Feldman PD, Young CA, Lehman DL, Breier A. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. International Journal of Geriatric Psychiatry. 19: 115-26. PMID 14758577 DOI: 10.1002/gps.1032  1
2004 Feldman PD, Hay LK, Deberdt W, Kennedy JS, Hutchins DS, Hay DP, Hardy TA, Hoffmann VP, Hornbuckle K, Breier A. Retrospective cohort study of diabetes mellitus and antipsychotic treatment in a geriatric population in the United States. Journal of the American Medical Directors Association. 5: 38-46. PMID 14706127 DOI: 10.1016/S1525-8610(04)70042-0  1
2004 Bitter I, Dossenbach MR, Brook S, Feldman PD, Metcalfe S, Gagiano CA, Füredi J, Bartko G, Janka Z, Banki CM, Kovacs G, Breier A. Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 28: 173-80. PMID 14687871 DOI: 10.1016/j.pnpbp.2003.09.033  1
2003 Wright P, Lindborg SR, Birkett M, Meehan K, Jones B, Alaka K, Ferchland-Howe I, Pickard A, Taylor CC, Roth J, Battaglia J, Bitter I, Chouinard G, Morris PL, Breier A. Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: antipsychotic efficacy and extrapyramidal safety during the first 24 hours of treatment. Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie. 48: 716-21. PMID 14733451  1
2003 Sowell M, Mukhopadhyay N, Cavazzoni P, Carlson C, Mudaliar S, Chinnapongse S, Ray A, Davis T, Breier A, Henry RR, Dananberg J. Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp. The Journal of Clinical Endocrinology and Metabolism. 88: 5875-80. PMID 14671184 DOI: 10.1210/jc.2002-021884  1
2003 Tohen M, Goldberg JF, Gonzalez-Pinto Arrillaga AM, Azorin JM, Vieta E, Hardy-Bayle MC, Lawson WB, Emsley RA, Zhang F, Baker RW, Risser RC, Namjoshi MA, Evans AR, Breier A. A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Archives of General Psychiatry. 60: 1218-26. PMID 14662554 DOI: 10.1001/archpsyc.60.12.1218  1
2003 Feldman PD, Kaiser CJ, Kennedy JS, Sutton VK, Tran PV, Tollefson GD, Zhang F, Breier A. Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years. The Journal of Clinical Psychiatry. 64: 998-1004. PMID 14628974  1
2003 Kennedy JS, Jeste D, Kaiser CJ, Golshan S, Maguire GA, Tollefson G, Sanger T, Bymaster FP, Kinon BJ, Dossenbach M, Gilmore JA, Breier A. Olanzapine vs haloperidol in geriatric schizophrenia: analysis of data from a double-blind controlled trial. International Journal of Geriatric Psychiatry. 18: 1013-20. PMID 14618553 DOI: 10.1002/gps.1007  1
2003 Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, Mitchell PB, Centorrino F, Risser R, Baker RW, Evans AR, Beymer K, Dube S, Tollefson GD, Breier A. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Archives of General Psychiatry. 60: 1079-88. PMID 14609883 DOI: 10.1001/archpsyc.60.11.1079  1
2003 Hardy T, Breier A. Patients on atypical antipsychotic drugs: another high-risk group for type 2 diabetes: response to Lean and Pajonk. Diabetes Care. 26: 3200-1. PMID 14578278 DOI: 10.2337/diacare.26.11.3200  1
2003 Elman I, Lukas S, Shoaf SE, Rott D, Adler C, Breier A. Effects of acute metabolic stress on the peripheral vasopressinergic system in schizophrenia. Journal of Psychopharmacology (Oxford, England). 17: 317-23. PMID 14513924 DOI: 10.1177/02698811030173014  1
2003 Woods SW, Breier A, Zipursky RB, Perkins DO, Addington J, Miller TJ, Hawkins KA, Marquez E, Lindborg SR, Tohen M, McGlashan TH. Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry. 54: 453-64. PMID 12915290 DOI: 10.1016/S0006-3223(03)00321-4  1
2003 Arango C, Breier A, McMahon R, Carpenter WT, Buchanan RW. The relationship of clozapine and haloperidol treatment response to prefrontal, hippocampal, and caudate brain volumes. The American Journal of Psychiatry. 160: 1421-7. PMID 12900303 DOI: 10.1176/appi.ajp.160.8.1421  1
2003 Wright P, Meehan K, Birkett M, Lindborg SR, Taylor CC, Morris P, Breier A. A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy. Clinical Therapeutics. 25: 1420-8. PMID 12867218 DOI: 10.1016/S0149-2918(03)80129-7  1
2003 Buse JB, Cavazzoni P, Hornbuckle K, Hutchins D, Breier A, Jovanovic L. A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. Journal of Clinical Epidemiology. 56: 164-70. PMID 12654411 DOI: 10.1016/S0895-4356(02)00588-7  1
2003 Cavazzoni P, Tanaka Y, Roychowdhury SM, Breier A, Allison DB. Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 13: 81-5. PMID 12650950 DOI: 10.1016/S0924-977X(02)00127-X  1
2003 Miller TJ, Zipursky RB, Perkins D, Addington J, Woods SW, Hawkins KA, Hoffman R, Preda A, Epstein I, Addington D, Lindborg S, Marquez E, Tohen M, Breier A, McGlashan TH. The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample. Schizophrenia Research. 61: 19-30. PMID 12648732 DOI: 10.1016/S0920-9964(02)00440-1  1
2003 McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller TJ, Woods SW, Hawkins KA, Hoffman R, Lindborg S, Tohen M, Breier A. The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design. Schizophrenia Research. 61: 7-18. PMID 12648731 DOI: 10.1016/S0920-9964(02)00439-5  1
2003 Sanger TM, Tohen M, Vieta E, Dunner DL, Bowden CL, Calabrese JR, Feldman PD, Jacobs TG, Breier A. Olanzapine in the acute treatment of bipolar I disorder with a history of rapid cycling. Journal of Affective Disorders. 73: 155-61. PMID 12507748 DOI: 10.1016/S0165-0327(02)00334-8  1
2002 Breier A, Sutton VK, Feldman PD, Kadam DL, Ferchland I, Wright P, Friedman JH. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease. Biological Psychiatry. 52: 438-45. PMID 12242060 DOI: 10.1016/S0006-3223(02)01392-6  1
2002 Shi L, Namjoshi MA, Zhang F, Gandhi G, Edgell ET, Tohen M, Breier A, Haro JM. Olanzapine versus haloperidol in the treatment of acute mania: clinical outcomes, health-related quality of life and work status. International Clinical Psychopharmacology. 17: 227-37. PMID 12177585  1
2002 Namjoshi MA, Rajamannar G, Jacobs T, Sanger TM, Risser R, Tohen MF, Breier A, Keck PE. Economic, clinical, and quality-of-life outcomes associated with olanzapine treatment in mania. Results from a randomized controlled trial. Journal of Affective Disorders. 69: 109-18. PMID 12103458 DOI: 10.1016/S0165-0327(01)00310-X  1
2002 Elman I, Goldstein DS, Green AI, Eisenhofer G, Folio CJ, Holmes CS, Pickar D, Breier A. Effects of risperidone on the peripheral noradrenegic system in patients with schizophrenia: a comparison with clozapine and placebo. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 27: 293-300. PMID 12093603 DOI: 10.1016/S0893-133X(02)00314-7  1
2002 Sowell MO, Mukhopadhyay N, Cavazzoni P, Shankar S, Steinberg HO, Breier A, Beasley CM, Dananberg J. Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo. The Journal of Clinical Endocrinology and Metabolism. 87: 2918-23. PMID 12050274 DOI: 10.1210/jcem.87.6.8599  1
2002 Tohen M, Baker RW, Altshuler LL, Zarate CA, Suppes T, Ketter TA, Milton DR, Risser R, Gilmore JA, Breier A, Tollefson GA. Olanzapine versus divalproex in the treatment of acute mania. The American Journal of Psychiatry. 159: 1011-7. PMID 12042191 DOI: 10.1176/appi.ajp.159.6.1011  1
2002 Breier A, Meehan K, Birkett M, David S, Ferchland I, Sutton V, Taylor CC, Palmer R, Dossenbach M, Kiesler G, Brook S, Wright P. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Archives of General Psychiatry. 59: 441-8. PMID 11982448  1
2002 Meehan KM, Wang H, David SR, Nisivoccia JR, Jones B, Beasley CM, Feldman PD, Mintzer JE, Beckett LM, Breier A. Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 26: 494-504. PMID 11927174 DOI: 10.1016/S0893-133X(01)00365-7  1
2002 Adler CM, Malhotra AK, Elman I, Pickar D, Breier A. Amphetamine-induced dopamine release and post-synaptic specific binding in patients with mild tardive dyskinesia. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 26: 295-300. PMID 11850144 DOI: 10.1016/S0893-133X(01)00309-8  1
2002 Tohen M, Chengappa KN, Suppes T, Zarate CA, Calabrese JR, Bowden CL, Sachs GS, Kupfer DJ, Baker RW, Risser RC, Keeter EL, Feldman PD, Tollefson GD, Breier A. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Archives of General Psychiatry. 59: 62-9. PMID 11779284  1
2001 Tohen M, Zhang F, Keck PE, Feldman PD, Risser RC, Tran PV, Breier A. Olanzapine versus haloperidol in schizoaffective disorder, bipolar type. Journal of Affective Disorders. 67: 133-40. PMID 11869760 DOI: 10.1016/S0165-0327(00)00303-7  1
2001 Mintzer J, Faison W, Street JS, Sutton VK, Breier A. Olanzapine in the treatment of anxiety symptoms due to Alzheimer's disease: a post hoc analysis. International Journal of Geriatric Psychiatry. 16: S71-7. PMID 11748790 DOI: 10.1002/1099-1166(200112)16:1+<::AID-GPS568>3.0.CO;2-M  1
2001 Street JS, Clark WS, Kadam DL, Mitan SJ, Juliar BE, Feldman PD, Breier A. Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with Alzheimer's dementia. International Journal of Geriatric Psychiatry. 16: S62-70. PMID 11748789 DOI: 10.1002/1099-1166(200112)16:1+<::AID-GPS569>3.0.CO;2-J  1
2001 Kennedy JS, Bymaster FP, Schuh L, Calligaro DO, Nomikos G, Felder CC, Bernauer M, Kinon BJ, Baker RW, Hay D, Roth HJ, Dossenbach M, Kaiser C, Beasley CM, Holcombe JH, ... ... Breier A, et al. A current review of olanzapine's safety in the geriatric patient: from pre-clinical pharmacology to clinical data. International Journal of Geriatric Psychiatry. 16: S33-61. PMID 11748788 DOI: 10.1002/1099-1166(200112)16:1+<::AID-GPS571>3.0.CO;2-5  1
2001 Kennedy JS, Zagar A, Bymaster F, Nomikos G, Trzepacz PT, Gilmore JA, Rotelli MD, Breier A, Tollefson G. The central cholinergic system profile of olanzapine compared with placebo in Alzheimer's disease. International Journal of Geriatric Psychiatry. 16: S24-32. PMID 11748787 DOI: 10.1002/1099-1166(200112)16:1+<::AID-GPS570>3.0.CO;2-8  1
2001 Meehan K, Zhang F, David S, Tohen M, Janicak P, Small J, Koch M, Rizk R, Walker D, Tran P, Breier A. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. Journal of Clinical Psychopharmacology. 21: 389-97. PMID 11476123 DOI: 10.1097/00004714-200108000-00006  1
2001 Wright P, Birkett M, David SR, Meehan K, Ferchland I, Alaka KJ, Saunders JC, Krueger J, Bradley P, San L, Bernardo M, Reinstein M, Breier A. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. The American Journal of Psychiatry. 158: 1149-51. PMID 11431240 DOI: 10.1176/appi.ajp.158.7.1149  1
2001 Elman I, Goldstein DS, Adler CM, Shoaf SE, Breier A. Inverse relationship between plasma epinephrine and testosterone levels during acute glucoprivation in healthy men. Life Sciences. 68: 1889-98. PMID 11292066 DOI: 10.1016/S0024-3205(01)00982-1  1
2001 Clark WS, Street JS, Feldman PD, Breier A. The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease. The Journal of Clinical Psychiatry. 62: 34-40. PMID 11235926  1
2001 Breier A. Introduction: a new era in the pharmacotherapy of psychotic disorders. The Journal of Clinical Psychiatry. 62: 3-5. PMID 11232750  1
2001 Tohen M, Jacobs TG, Grundy SL, McElroy SL, Banov MC, Janicak PG, Sanger T, Risser R, Zhang F, Toma V, Francis J, Tollefson GD, Breier A. Efficacy of olanzapine in acute bipolar mania - A double-blind, placebo-controlled study | Eficácia da olanzapina na fase aguda da mania bipolar - Um estudo duplocego, controlado por placebo Revista De Psiquiatria Clinica. 28: 218.  1
2000 Edgell ET, Andersen SW, Johnstone BM, Dulisse B, Revicki D, Breier A. Olanzapine versus risperidone. A prospective comparison of clinical and economic outcomes in schizophrenia. Pharmacoeconomics. 18: 567-79. PMID 11227395  1
2000 David SR, Taylor CC, Kinon BJ, Breier A. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clinical Therapeutics. 22: 1085-96. PMID 11048906 DOI: 10.1016/S0149-2918(00)80086-7  1
2000 Street JS, Clark WS, Gannon KS, Cummings JL, Bymaster FP, Tamura RN, Mitan SJ, Kadam DL, Sanger TM, Feldman PD, Tollefson GD, Breier A. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Archives of General Psychiatry. 57: 968-76. PMID 11015815  1
2000 Breier A, Buchanan RW, Irish D, Carpenter WT. Clozapine treatment of outpatients with schizophrenia: outcome and long-term response patterns. 1993. Psychiatric Services (Washington, D.C.). 51: 1249-53. PMID 11013322  1
2000 Hamilton SH, Edgell ET, Revicki DA, Breier A. Functional outcomes in schizophrenia: a comparison of olanzapine and haloperidol in a European sample. International Clinical Psychopharmacology. 15: 245-55. PMID 10993126  1
2000 Carpenter WT, Breier A, Buchanan RW, Kirkpatrick B, Shepard P, Weiner E. Mazindol treatment of negative symptoms. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 23: 365-74. PMID 10989263 DOI: 10.1016/S0893-133X(00)00115-9  1
2000 Tohen M, Jacobs TG, Grundy SL, McElroy SL, Banov MC, Janicak PG, Sanger T, Risser R, Zhang F, Toma V, Francis J, Tollefson GD, Breier A. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group. Archives of General Psychiatry. 57: 841-9. PMID 10986547  1
2000 Gómez JC, Sacristán JA, Hernández J, Breier A, Ruiz Carrasco P, Antón Saiz C, Fontova Carbonell E. The safety of olanzapine compared with other antipsychotic drugs: results of an observational prospective study in patients with schizophrenia (EFESO Study). Pharmacoepidemiologic Study of Olanzapine in Schizophrenia. The Journal of Clinical Psychiatry. 61: 335-43. PMID 10847307  1
2000 Adler CM, Elman I, Weisenfeld N, Kestler L, Pickar D, Breier A. Effects of acute metabolic stress on striatal dopamine release in healthy volunteers. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 22: 545-50. PMID 10731630 DOI: 10.1016/S0893-133X(99)00153-0  1
2000 Watabe H, Endres CJ, Breier A, Schmall B, Eckelman WC, Carson RE. Measurement of dopamine release with continuous infusion of [11C]raclopride: optimization and signal-to-noise considerations. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 41: 522-30. PMID 10716328  1
2000 Purdon SE, Jones BD, Stip E, Labelle A, Addington D, David SR, Breier A, Tollefson GD. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. Archives of General Psychiatry. 57: 249-58. PMID 10711911  1
2000 Bertolino A, Breier A, Callicott JH, Adler C, Mattay VS, Shapiro M, Frank JA, Pickar D, Weinberger DR. The relationship between dorsolateral prefrontal neuronal N-acetylaspartate and evoked release of striatal dopamine in schizophrenia. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 22: 125-32. PMID 10649825 DOI: 10.1016/S0893-133X(99)00096-2  1
2000 Kestler LP, Malhotra AK, Finch C, Adler C, Breier A. The relation between dopamine D2 receptor density and personality: preliminary evidence from the NEO personality inventory-revised. Neuropsychiatry, Neuropsychology, and Behavioral Neurology. 13: 48-52. PMID 10645736  1
1999 Adler CM, Malhotra AK, Elman I, Goldberg T, Egan M, Pickar D, Breier A. Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. The American Journal of Psychiatry. 156: 1646-9. PMID 10518181  1
1999 Breier A, Berg PH. The psychosis of schizophrenia: prevalence, response to atypical antipsychotics, and prediction of outcome. Biological Psychiatry. 46: 361-4. PMID 10435201 DOI: 10.1016/S0006-3223(99)00040-2  1
1999 Kosmidis MH, Breier A, Fantie BD. Avoidance learning in schizophrenia: a dissociation between the effects of aversive and non-aversive stimuli. Schizophrenia Research. 38: 51-9. PMID 10427610 DOI: 10.1016/S0920-9964(98)00181-9  1
1999 Rietschel M, Kennedy JL, Macciardi F, Meltzer HY. Application of pharmacogenetics to psychotic disorders: the first consensus conference. The Consensus Group for Outcome Measures in Psychoses for Pharmacological Studies. Schizophrenia Research. 37: 191-6. PMID 10374654 DOI: 10.1016/S0920-9964(98)00153-4  1
1999 Breier A. Cognitive deficit in schizophrenia and its neurochemical basis. The British Journal of Psychiatry. Supplement. 16-8. PMID 10211135  1
1999 Breier A, Su TP, Malhotra AK, Elman I, Adler CM, Weisenfeld NI, Pickar D. Effects of atypical antipsychotic drug treatment on amphetamine-induced striatal dopamine release in patients with psychotic disorders. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 20: 340-5. PMID 10088134 DOI: 10.1016/S0893-133X(98)00126-2  1
1999 Carpenter WT, Buchanan RW, Kirkpatrick B, Lann HD, Breier AF, Summerfelt AT. Comparative effectiveness of fluphenazine decanoate injections every 2 weeks versus every 6 weeks. The American Journal of Psychiatry. 156: 412-8. PMID 10080557  1
1999 Breier A, Hamilton SH. Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia. Biological Psychiatry. 45: 403-11. PMID 10071708 DOI: 10.1016/S0006-3223(98)00291-1  1
1999 Breier AF, Malhotra AK, Su TP, Pinals DA, Elman I, Adler CM, Lafargue RT, Clifton A, Pickar D. Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. The American Journal of Psychiatry. 156: 294-8. PMID 9989566  1
1999 Elman I, Goldstein DS, Eisenhofer G, Folio J, Malhotra AK, Adler CM, Pickar D, Breier A. Mechanism of peripheral noradrenergic stimulation by clozapine. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 20: 29-34. PMID 9885782 DOI: 10.1016/S0893-133X(98)00047-5  1
1999 Elman I, Sokoloff L, Adler CM, Weisenfeld N, Breier A. The effects of pharmacological doses of 2-deoxyglucose on cerebral blood flow in healthy volunteers. Brain Research. 815: 243-9. PMID 9878763 DOI: 10.1016/S0006-8993(98)01137-8  1
1999 Breier A, Lieberman JA. Papers from the Symposium 'New Antipsychotic Drugs: Special Issues and Indications' 20-21 February, 1998 Marco Island, Florida. Introduction Schizophrenia Research. 35. DOI: 10.1016/S0920-9964(98)00157-1  1
1998 Malhotra AK, Breier A, Goldman D, Picken L, Pickar D. The apolipoprotein E epsilon 4 allele is associated with blunting of ketamine-induced psychosis in schizophrenia. A preliminary report. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 19: 445-8. PMID 9778666 DOI: 10.1016/S0893-133X(98)00031-1  1
1998 Breier A, Kestler L, Adler C, Elman I, Wiesenfeld N, Malhotra A, Pickar D. Dopamine D2 receptor density and personal detachment in healthy subjects. The American Journal of Psychiatry. 155: 1440-2. PMID 9766779  1
1998 Malhotra AK, Goldman D, Mazzanti C, Clifton A, Breier A, Pickar D. A functional serotonin transporter (5-HTT) polymorphism is associated with psychosis in neuroleptic-free schizophrenics. Molecular Psychiatry. 3: 328-32. PMID 9702741  1
1998 Elman I, Adler CM, Malhotra AK, Bir C, Pickar D, Breier A. Effect of acute metabolic stress on pituitary-adrenal axis activation in patients with schizophrenia. The American Journal of Psychiatry. 155: 979-81. PMID 9659871  1
1998 Buchanan RW, Breier A, Kirkpatrick B, Ball P, Carpenter WT. Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. The American Journal of Psychiatry. 155: 751-60. PMID 9619146  1
1998 Adler CM, Goldberg TE, Malhotra AK, Pickar D, Breier A. Effects of ketamine on thought disorder, working memory, and semantic memory in healthy volunteers. Biological Psychiatry. 43: 811-6. PMID 9611670 DOI: 10.1016/S0006-3223(97)00556-8  1
1998 Breier A, Adler CM, Weisenfeld N, Su TP, Elman I, Picken L, Malhotra AK, Pickar D. Effects of NMDA antagonism on striatal dopamine release in healthy subjects: application of a novel PET approach. Synapse (New York, N.Y.). 29: 142-7. PMID 9593104 DOI: 10.1002/(SICI)1098-2396(199806)29:2<142::AID-SYN5>3.0.CO;2-7  1
1998 Bertolino A, Callicott JH, Elman I, Mattay VS, Tedeschi G, Frank JA, Breier A, Weinberger DR. Regionally specific neuronal pathology in untreated patients with schizophrenia: a proton magnetic resonance spectroscopic imaging study. Biological Psychiatry. 43: 641-8. PMID 9582997 DOI: 10.1016/S0006-3223(97)00555-6  1
1998 Pinals DA, Malhotra AK, Breier A, Pickar D. Informed consent in schizophrenia research. Psychiatric Services (Washington, D.C.). 49: 244. PMID 9575016  1
1998 Malhotra AK, Goldman D, Buchanan RW, Rooney W, Clifton A, Kosmidis MH, Breier A, Pickar D. The dopamine D3 receptor (DRD3) Ser9Gly polymorphism and schizophrenia: a haplotype relative risk study and association with clozapine response. Molecular Psychiatry. 3: 72-5. PMID 9491816  1
1998 Breier A, Elman I, Goldstein DS. Norepinephrine and schizophrenia: a new hypothesis for antipsychotic drug action. Advances in Pharmacology (San Diego, Calif.). 42: 785-8. PMID 9328015 DOI: 10.1016/S1054-3589(08)60864-9  1
1997 Elman I, Breier A. Effects of acute metabolic stress on plasma progesterone and testosterone in male subjects: relationship to pituitary-adrenocortical axis activation. Life Sciences. 61: 1705-12. PMID 9363986 DOI: 10.1016/S0024-3205(97)00776-5  1
1997 Kirkpatrick B, Litman D, Kim JW, Vladar K, Breier A, Buchanan RW. Failure of fusion of the septum pellucidum and the heterogeneity of schizophrenia. The Journal of Nervous and Mental Disease. 185: 639-41. PMID 9345255 DOI: 10.1097/00005053-199710000-00008  1
1997 Su TP, Malhotra AK, Hadd K, Breier A, Pickar D. D2 dopamine receptor occupancy: a crossover comparison of risperidone with clozapine therapy in schizophrenic patients. Archives of General Psychiatry. 54: 972-3. PMID 9337781  1
1997 Malhotra AK, Adler CM, Kennison SD, Elman I, Pickar D, Breier A. Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: a study with ketamine. Biological Psychiatry. 42: 664-8. PMID 9325559 DOI: 10.1016/S0006-3223(96)00546-X  1
1997 Pickar D, Malhotra AK, Rooney W, Breier A, Goldman D. Apolipoprotein E epsilon 4 and clinical phenotype in schizophrenia. Lancet. 350: 930-1. PMID 9314875 DOI: 10.1016/S0140-6736(05)63266-7  1
1997 Endres CJ, Kolachana BS, Saunders RC, Su T, Weinberger D, Breier A, Eckelman WC, Carson RE. Kinetic modeling of [11C]raclopride: combined PET-microdialysis studies. Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism. 17: 932-42. PMID 9307606 DOI: 10.1097/00004647-199709000-00002  1
1997 Malhotra AK, Pinals DA, Adler CM, Elman I, Clifton A, Pickar D, Breier A. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 17: 141-50. PMID 9272481 DOI: 10.1016/S0893-133X(97)00036-5  1
1997 Breier A, Malhotra AK, Pinals DA, Weisenfeld NI, Pickar D. Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. The American Journal of Psychiatry. 154: 805-11. PMID 9167508  1
1997 Carson RE, Breier A, de Bartolomeis A, Saunders RC, Su TP, Schmall B, Der MG, Pickar D, Eckelman WC. Quantification of amphetamine-induced changes in [11C]raclopride binding with continuous infusion. Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism. 17: 437-47. PMID 9143226 DOI: 10.1097/00004647-199704000-00009  1
1997 Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A, Weinberger DR, Weisenfeld N, Malhotra AK, Eckelman WC, Pickar D. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proceedings of the National Academy of Sciences of the United States of America. 94: 2569-74. PMID 9122236 DOI: 10.1073/pnas.94.6.2569  1
1997 Waltrip RW, Buchanan RW, Carpenter WT, Kirkpatrick B, Summerfelt A, Breier A, Rubin SA, Carbone KM. Borna disease virus antibodies and the deficit syndrome of schizophrenia. Schizophrenia Research. 23: 253-7. PMID 9075304 DOI: 10.1016/S0920-9964(96)00114-4  1
1997 Buchanan RW, Strauss ME, Breier A, Kirkpatrick B, Carpenter WT. Attentional impairments in deficit and nondeficit forms of schizophrenia. The American Journal of Psychiatry. 154: 363-70. PMID 9054784  1
1996 Pinals DA, Malhotra AK, Missar CD, Pickar D, Breier A. Lack of gender differences in neuroleptic response in patients with schizophrenia. Schizophrenia Research. 22: 215-22. PMID 9000318 DOI: 10.1016/S0920-9964(96)00067-9  1
1996 Pickar D, Su TP, Weinberger DR, Coppola R, Malhotra AK, Knable MB, Lee KS, Gorey J, Bartko JJ, Breier A, Hsiao J. Individual variation in D2 dopamine receptor occupancy in clozapine-treated patients. The American Journal of Psychiatry. 153: 1571-8. PMID 8942453  0.44
1996 Malhotra AK, Goldman D, Ozaki N, Rooney W, Clifton A, Buchanan RW, Breier A, Pickar D. Clozapine response and the 5HT2C Cys23Ser polymorphism. Neuroreport. 7: 2100-2. PMID 8930967  0.44
1996 Malhotra AK, Pinals DA, Weingartner H, Sirocco K, Missar CD, Pickar D, Breier A. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 14: 301-7. PMID 8703299 DOI: 10.1016/0893-133X(95)00137-3  1
1996 Malhotra AK, Goldman D, Ozaki N, Breier A, Buchanan R, Pickar D. Lack of association between polymorphisms in the 5-HT2A receptor gene and the antipsychotic response to clozapine. The American Journal of Psychiatry. 153: 1092-4. PMID 8678181  1
1996 Malhotra AK, Goldman D, Buchanan R, Breier A, Pickar D. 5HT 2a receptor T102C polymorphism and schizophrenia. Lancet. 347: 1830-1. PMID 8667937 DOI: 10.1016/S0140-6736(96)91650-5  1
1996 Frazier JA, Giedd JN, Hamburger SD, Albus KE, Kaysen D, Vaituzis AC, Rajapakse JC, Lenane MC, McKenna K, Jacobsen LK, Gordon CT, Breier A, Rapoport JL. Brain anatomic magnetic resonance imaging in childhood-onset schizophrenia. Archives of General Psychiatry. 53: 617-24. PMID 8660128  1
1996 Bustillo JR, Buchanan RW, Irish D, Breier A. Differential effect of clozapine on weight: a controlled study. The American Journal of Psychiatry. 153: 817-9. PMID 8633697  1
1996 Frazier JA, Giedd JN, Kaysen D, Albus K, Hamburger S, Alaghband-Rad J, Lenane MC, McKenna K, Breier A, Rapoport JL. Childhood-onset schizophrenia: brain MRI rescan after 2 years of clozapine maintenance treatment. The American Journal of Psychiatry. 153: 564-6. PMID 8599409  1
1995 Waltrip RW, Buchanan RW, Summerfelt A, Breier A, Carpenter WT, Bryant NL, Rubin SA, Carbone KM. Borna disease virus and schizophrenia. Psychiatry Research. 56: 33-44. PMID 7792340 DOI: 10.1016/0165-1781(94)02600-N  1
1995 Schreiber JL, Breier A, Pickar D. Expressed emotion. Trait or state? The British Journal of Psychiatry : the Journal of Mental Science. 166: 647-9. PMID 7620751  1
1995 Breier A. Serotonin, schizophrenia and antipsychotic drug action. Schizophrenia Research. 14: 187-202. PMID 7539288 DOI: 10.1016/0920-9964(94)00043-8  1
1995 Breier A. The management of treatment-resistant schizophrenia Current Opinion in Psychiatry. 8: 41-44. DOI: 10.1097/00001504-199501000-00010  1
1994 Breier A, Buchanan RW, Waltrip RW, Listwak S, Holmes C, Goldstein DS. The effect of clozapine on plasma norepinephrine: relationship to clinical efficacy. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 10: 1-7. PMID 8179790 DOI: 10.1038/npp.1994.1  0.52
1994 Kirkpatrick B, Buchanan RW, Breier A, Carpenter WT. Depressive symptoms and the deficit syndrome of schizophrenia. The Journal of Nervous and Mental Disease. 182: 452-5. PMID 8040655  1
1994 Breier A. Clozapine and noradrenergic function: support for a novel hypothesis for superior efficacy. The Journal of Clinical Psychiatry. 55: 122-5. PMID 7961555  1
1994 Buchanan RW, Koeppl P, Breier A. Stability of neurological signs with clozapine treatment. Biological Psychiatry. 36: 198-200. PMID 7948457 DOI: 10.1016/0006-3223(94)91225-4  1
1994 Buchanan RW, Strauss ME, Kirkpatrick B, Holstein C, Breier A, Carpenter WT. Neuropsychological impairments in deficit vs nondeficit forms of schizophrenia. Archives of General Psychiatry. 51: 804-11. PMID 7944870 DOI: 10.1001/archpsyc.1994.03950100052005  1
1994 Elkashef AM, Buchanan RW, Gellad F, Munson RC, Breier A. Basal ganglia pathology in schizophrenia and tardive dyskinesia: an MRI quantitative study. The American Journal of Psychiatry. 151: 752-5. PMID 7909412  1
1994 Buchanan RW, Holstein C, Breier A. The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biological Psychiatry. 36: 717-25. PMID 7858067 DOI: 10.1016/0006-3223(94)90082-5  1
1993 Kirkpatrick B, Buchanan RW, Breier A, Carpenter WT. Case identification and stability of the deficit syndrome of schizophrenia. Psychiatry Research. 47: 47-56. PMID 8516416 DOI: 10.1016/0165-1781(93)90054-K  1
1993 Buchanan RW, Breier A, Kirkpatrick B, Elkashef A, Munson RC, Gellad F, Carpenter WT. Structural abnormalities in deficit and nondeficit schizophrenia. The American Journal of Psychiatry. 150: 59-65. PMID 8417581  1
1993 Schreiber JL, Breier A, Pickar D. Hospital vs. community. Hospital & Community Psychiatry. 44: 795. PMID 8375849  1
1993 Breier A, Crane AM, Kennedy C, Sokoloff L. The effects of pharmacologic doses of 2-deoxy-D-glucose on local cerebral blood flow in the awake, unrestrained rat. Brain Research. 618: 277-82. PMID 8374758 DOI: 10.1016/0006-8993(93)91276-X  1
1993 Breier A, Davis OR, Buchanan RW, Moricle LA, Munson RC. Effects of metabolic perturbation on plasma homovanillic acid in schizophrenia. Relationship to prefrontal cortex volume. Archives of General Psychiatry. 50: 541-50. PMID 8317948 DOI: 10.1001/archpsyc.1993.01820190043005  1
1993 Breier A, Kirkpatrick B, Buchanan RW. Clozapine attenuates meta-chlorophenylpiperazine (mCPP)-induced plasma cortisol increases in schizophrenia. Biological Psychiatry. 34: 492-4. PMID 8268334 DOI: 10.1016/0006-3223(93)90241-5  1
1993 Wolkowitz OM, Coppola R, Breier A, Doran AR, Rubinow DR, Berrettini WH, Kling MA, Pickar D. Quantitative electroencephalographic correlates of steroid administration in man. Neuropsychobiology. 27: 224-30. PMID 8232843  1
1993 Breier A, Buchanan RW, Irish D, Carpenter WT. Clozapine treatment of outpatients with schizophrenia: outcome and long-term response patterns. Hospital & Community Psychiatry. 44: 1145-9. PMID 8132186  1
1993 Wolkowitz OM, Weingartner H, Rubinow DR, Jimerson D, Kling M, Berretini W, Thompson K, Breier A, Doran A, Reus VI. Steroid modulation of human memory: biochemical correlates. Biological Psychiatry. 33: 744-6. PMID 8102553 DOI: 10.1016/0006-3223(93)90125-W  1
1993 Hommer D, Weingartner H, Breier A. Dissociation of benzodiazepine-induced amnesia from sedation by flumazenil pretreatment. Psychopharmacology. 112: 455-60. PMID 7871057 DOI: 10.1007/BF02244894  1
1992 Puryear DA, Carson C, Fuentes R, Valls T. Subjective conclusions about schizophrenia. Archives of General Psychiatry. 49: 74-6. PMID 1728253 DOI: 10.1001/archpsyc.1992.01820010074010  1
1992 Albus M, Zahn TP, Breier A. Anxiogenic properties of yohimbine. II. Influence of experimental set and setting. European Archives of Psychiatry and Clinical Neuroscience. 241: 345-51. PMID 1504111 DOI: 10.1007/BF02191959  1
1992 Albus M, Zahn TP, Breier A. Anxiogenic properties of yohimbine. I. Behavioral, physiological and biochemical measures. European Archives of Psychiatry and Clinical Neuroscience. 241: 337-44. PMID 1504110 DOI: 10.1007/BF02191958  1
1992 Breier A, Buchanan RW, Elkashef A, Munson RC, Kirkpatrick B, Gellad F. Brain morphology and schizophrenia. A magnetic resonance imaging study of limbic, prefrontal cortex, and caudate structures. Archives of General Psychiatry. 49: 921-6. PMID 1449382 DOI: 10.1001/archpsyc.1992.01820120009003  1
1992 Breier A, Buchanan RW. The effects of metabolic stress on plasma progesterone in healthy volunteers and schizophrenic patients. Life Sciences. 51: 1527-34. PMID 1435061 DOI: 10.1016/0024-3205(92)90563-5  1
1992 Breier A, Schreiber JL, Dyer J, Pickar D. Course of illness and predictors of outcome in chronic schizophrenia: implications for pathophysiology. The British Journal of Psychiatry. Supplement. 38-43. PMID 1389040  1
1992 Goldstein DS, Breier A, Wolkowitz OM, Pickar D, Lenders JW. Plasma levels of catecholamines and corticotrophin during acute glucopenia induced by 2-deoxy-D-glucose in normal man. Clinical Autonomic Research : Official Journal of the Clinical Autonomic Research Society. 2: 359-66. PMID 1337845 DOI: 10.1007/BF01831392  1
1992 Breier A, Davis O, Buchanan R, Listwak SJ, Holmes C, Pickar D, Goldstein DS. Effects of alprazolam on pituitary-adrenal and catecholaminergic responses to metabolic stress in humans. Biological Psychiatry. 32: 880-90. PMID 1334713  0.52
1992 Breier A. Effects of alprazolam on metabolic stress-related alterations in HPA axis and catecholamine function in humans European Neuropsychopharmacology. 2: 377. DOI: 10.1016/0924-977X(92)90230-6  1
1992 Breier A, Schreiber JL, Pickar D, Dyer J. Long-term Outcome in Chronic Schizophrenia-Reply Archives of General Psychiatry. 49: 503. DOI: 10.1001/archpsyc.1992.01820060083016  1
1991 Breier A, Davis OR, Buchanan RW. Alprazolam attenuates metabolic stress-induced neuroendocrine and behavioral effects in humans. Psychopharmacology. 104: 479-84. PMID 1780418 DOI: 10.1007/BF02245653  1
1991 Breier A. Panic disorder: clinical features, neurobiology, and pharmacotherapy. New York State Journal of Medicine. 91: 43S-47S. PMID 1771059  1
1991 Breier A, Schreiber JL, Dyer J, Pickar D. National Institute of Mental Health longitudinal study of chronic schizophrenia. Prognosis and predictors of outcome. Archives of General Psychiatry. 48: 239-46. PMID 1671741 DOI: 10.1001/archpsyc.1991.01810270051007  1
1990 Wolkowitz OM, Reus VI, Weingartner H, Thompson K, Breier A, Doran A, Rubinow D, Pickar D. Cognitive effects of corticosteroids. The American Journal of Psychiatry. 147: 1297-303. PMID 2399996  1
1990 Wolkowitz OM, Papadopoulos NM, Costello R, Breier A, Doran AR, Pickar D, Rubinow D. Prednisone effects on blood-brain barrier permeability and CNS IgG synthesis in healthy humans. Psychoneuroendocrinology. 15: 155-8. PMID 2359811 DOI: 10.1016/0306-4530(90)90024-4  1
1990 Breier A, Wolkowitz OM, Roy A, Potter WZ, Pickar D. Plasma norepinephrine in chronic schizophrenia. The American Journal of Psychiatry. 147: 1467-70. PMID 2221157  1
1990 Weisse CS, Pato CN, McAllister CG, Littman R, Breier A, Paul SM, Baum A. Differential effects of controllable and uncontrollable acute stress on lymphocyte proliferation and leukocyte percentages in humans. Brain, Behavior, and Immunity. 4: 339-51. PMID 2092868 DOI: 10.1016/0889-1591(90)90037-Q  1
1990 Breier A, Paul SM. The GABAA/benzodiazepine receptor: Implications for the molecular basis of anxiety Journal of Psychiatric Research. 24: 91-104. PMID 1980704 DOI: 10.1016/0022-3956(90)90040-W  1
1990 Wolkowitz OM, Rubinow D, Doran AR, Breier A, Berrettini WH, Kling MA, Pickar D. Prednisone effects on neurochemistry and behavior. Preliminary findings. Archives of General Psychiatry. 47: 963-8. PMID 1977371 DOI: 10.1001/archpsyc.1990.01810220079010  1
1990 Schreiber JL, Breier A, Pickar D. Characteristics of patients selected for treatment on a schizophrenia research unit. Hospital & Community Psychiatry. 41: 441-3. PMID 1970550  1
1990 Pickar D, Breier A, Hsiao JK, Doran AR, Wolkowitz OM, Pato CN, Konicki PE, Potter WZ. Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis. Implications for regional brain dysfunction in schizophrenia. Archives of General Psychiatry. 47: 641-8. PMID 1694425 DOI: 10.1001/archpsyc.1990.01810190041006  1
1989 Wolkowitz OM, Doran A, Breier A, Roy A, Pickar D. Specificity of plasma HVA response to dexamethasone in psychotic depression Psychiatry Research. 29: 177-186. PMID 2798596 DOI: 10.1016/0165-1781(89)90032-2  1
1989 Breier A. Experimental approaches to human stress research: Assessment of neurobiological mechanisms of stress in volunteers and psychiatric patients Biological Psychiatry. 26: 438-462. PMID 2551397 DOI: 10.1016/0006-3223(89)90066-8  1
1988 Breier A. Stress isn't always bad Hospital and Community Psychiatry. 39: 591. PMID 3402917  1
1988 Breier A. Small sample studies: Unique contributions for large sample outcome studies Schizophrenia Bulletin. 14: 589-593. PMID 3064285  1
1988 Pickar D, Breier A, Kelsoe J. Plasma homovanillic acid as an index of central dopaminergic activity: studies in schizophrenic patients Annals of the New York Academy of Sciences. 537: 339-346. PMID 2904783  1
1988 Breier A, Wolkowitz OM, Doran AR, Bellar S, Pickar D. Neurobiological effects of lumbar puncture stress in psychiatric patients and healthy volunteers. Psychiatry Research. 25: 187-94. PMID 2845460 DOI: 10.1016/0165-1781(88)90050-9  1
1988 Charney DS, Price LH, Breier A. The Course of Panic Attacks and Agoraphobia-Reply Archives of General Psychiatry. 45: 502. DOI: 10.1001/archpsyc.1988.01800290124016  1
1986 Charney DS, Heninger GR, Price LH, Breier A. Major depression and panic disorder: Diagnostic and neurobiological relationships Psychopharmacology Bulletin. 22: 503-511. PMID 3774939  1
1986 Breier A, Charney DS, Heninger GR. Agoraphobia With Panic Attacks: Development, Diagnostic Stability, and Course of Illness Archives of General Psychiatry. 43: 1029-1036. PMID 3767595 DOI: 10.1001/archpsyc.1986.01800110015003  1
1986 Breier A, Charney DS, Heninger GR. Intravenous diazepam fails to change growth hormone and cortisol secretion in humans Psychiatry Research. 18: 293-299. PMID 3749390 DOI: 10.1016/0165-1781(86)90014-4  1
1986 Doran AR, Breier A, Roy A. Differential diagnosis and diagnostic systems in schizophrenia. The Psychiatric Clinics of North America. 9: 17-33. PMID 3515329  1
1986 Charney DS, Breier A, Jatlow PI, Heninger GR. Behavioral, biochemical, and blood pressure responses to alprazolam in healthy subjects: Interactions with Yohimbine Psychopharmacology. 88: 133-140. PMID 3081923 DOI: 10.1007/BF00652229  1
1986 Wolkowitz OM, Doran AR, Breier A, Cohen MR, Pickar D. Endogenous opioid regulation of hypothalamo-pituitary-adrenal axis activity in schizophrenia. Biological Psychiatry. 21: 366-73. PMID 2869791 DOI: 10.1016/0006-3223(86)90164-2  1
1985 Roy A, Breier A, Doran AR, Pickar D. Life events in depression. Relationship to subtypes. Journal of Affective Disorders. 9: 143-8. PMID 2932487 DOI: 10.1016/0165-0327(85)90093-X  1
1985 Breier A, Charney DS, Heninger GR. The diagnostic validity of anxiety disorders and their relationship to depressive illness American Journal of Psychiatry. 142: 787-797. PMID 2861752  1
1984 Charney DS, Heninger GR, Breier A. Noradrenergic Function in Panic Anxiety: Effects of Yohimbine in Healthy Subjects and Patients With Agoraphobia and Panic Disorder Archives of General Psychiatry. 41: 751-763. PMID 6742977 DOI: 10.1001/archpsyc.1984.01790190025003  1
1984 Breier A, Ginsberg EM, Charney DS. Seminal emission induced by tricyclic antidepressant American Journal of Psychiatry. 141: 610-611. PMID 6703149  1
1984 Breier A, Astrachan BM. Characterization of schizophrenic patients who commit suicide American Journal of Psychiatry. 141: 206-209. PMID 6691481  1
1984 Breier A, Charney DS, Heninger GR. Major Depression in Patients With Agoraphobia and Panic Disorder Archives of General Psychiatry. 41: 1129-1135. PMID 6508503 DOI: 10.1001/archpsyc.1984.01790230015002  1
1984 Breier A, Strauss JS. The role of social relationships in the recovery from psychotic disorders American Journal of Psychiatry. 141: 949-955. PMID 6465369  1
1984 Breier A, Charney DS, Nelson JC. Seizures induced by abrupt discontinuation of alprazolam American Journal of Psychiatry. 141: 1606-1607. PMID 6150649  1
1983 Breier A, Strauss JS. Self-control in Psychotic Disorders Archives of General Psychiatry. 40: 1141-1145. PMID 6625862 DOI: 10.1001/archpsyc.1983.01790090103016  1
1981 Breier A, Hitzemann RJ, Hirschowitz J, Garver DL. Kinetic analysis of platelet monoamine oxidase in chronic schizophrenia Life Sciences. 28: 1947-1951. PMID 7253802 DOI: 10.1016/0024-3205(81)90303-9  1
Show low-probability matches.